<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: commercialize products", fill: "#c66"},
{source: "3: commercialize products", target: "3: investment", fill: "#c66"},
{source: "3: investment", target: "3: product development", fill: "#c66"},
{source: "3: product development", target: "3: manufacturing efforts", fill: "#c66"},
{source: "3: commercialize products", target: "6: also devoting", fill: "#c0c"},
{source: "6: also devoting", target: "6: establishment", fill: "#c0c"},
{source: "6: establishment", target: "6: manufacturing capabilities both", fill: "#c0c"},
{source: "6: manufacturing capabilities both", target: "6: support clinical testing", fill: "#c0c"},
{source: "6: support clinical testing", target: "6: commercialization", fill: "#c0c"},
{source: "6: also devoting", target: "8: commercialize", fill: "#6a5acd"},
{source: "8: commercialize", target: "8: must rigorously test", fill: "#6a5acd"},
{source: "8: must rigorously test", target: "8: laboratory", fill: "#6a5acd"},
{source: "8: laboratory", target: "8: human studies", fill: "#6a5acd"},
{source: "8: commercialize", target: "9: cannot assure", fill: "#8f00ff"},
{source: "9: cannot assure", target: "9: study will yield products", fill: "#8f00ff"},
{source: "9: cannot assure", target: "10: additional costs", fill: "#00009c"},
{source: "10: additional costs", target: "10: activities", fill: "#00009c"},
{source: "10: additional costs", target: "14: Commercialization ", fill: "#701c1c"},
{source: "14: Commercialization ", target: "14: failure inherent", fill: "#701c1c"},
{source: "14: failure inherent", target: "14: development", fill: "#701c1c"},
{source: "14: development", target: "14: products based", fill: "#701c1c"},
{source: "14: products based", target: "14: on innovative technologies", fill: "#701c1c"},
{source: "14: on innovative technologies", target: "14: risks associated with drug development", fill: "#701c1c"},
{source: "14: risks associated with drug development", target: "14: generally", fill: "#701c1c"},
{source: "14: Commercialization ", target: "15: possibility", fill: "#40826d"},
{source: "15: possibility", target: "15: technologies", fill: "#40826d"},
{source: "15: technologies", target: "15: technologies will", fill: "#40826d"},
{source: "15: technologies will", target: "15: ineffective", fill: "#40826d"},
{source: "15: ineffective", target: "15: otherwise fail", fill: "#40826d"},
{source: "15: otherwise fail", target: "15: necessary regulatory clearances", fill: "#40826d"},
{source: "15: necessary regulatory clearances", target: "15: effective will", fill: "#40826d"},
{source: "15: effective will", target: "15: difficult", fill: "#40826d"},
{source: "15: difficult", target: "15: manufacture", fill: "#40826d"},
{source: "15: manufacture", target: "15: proprietary", fill: "#40826d"},
{source: "15: proprietary", target: "15: will prevent us", fill: "#40826d"},
{source: "15: will prevent us", target: "15: collaborators from exploiting technologies", fill: "#40826d"},
{source: "15: collaborators from exploiting technologies", target: "15: marketing products", fill: "#40826d"},
{source: "15: marketing products", target: "15: third parties will market", fill: "#40826d"},
{source: "15: third parties will market", target: "15: equivalent products", fill: "#40826d"},
{source: "15: possibility", target: "32: In December ", fill: "#e52b50"},
{source: "32: In December ", target: "32: entered into", fill: "#e52b50"},
{source: "32: entered into", target: "32: agreement", fill: "#e52b50"},
{source: "32: agreement", target: "32: CoGenesys ", fill: "#e52b50"},
{source: "32: CoGenesys ", target: "32: independent company", fill: "#e52b50"},
{source: "32: independent company", target: "32: transaction", fill: "#e52b50"},
{source: "32: transaction", target: "32: treated as", fill: "#e52b50"},
{source: "32: treated as", target: "32: accounting purposes", fill: "#e52b50"},
{source: "32: In December ", target: "73: collaboration partners", fill: "#880085"},
{source: "73: collaboration partners", target: "73: marketing approval", fill: "#880085"},
{source: "73: marketing approval", target: "73: development efforts", fill: "#880085"},
{source: "73: collaboration partners", target: "START_HERE", fill: "#880085"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Negotiation</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2011_military_intervention_in_Libya">2011 military intervention in Libya</a></td>
      <td>On 19 March 2011, a multi-state NATO-led coalition began a military intervention in Libya, to implement United Nations Security Council Resolution 1973, in response to events during the First Libyan Civil War. With ten votes in favour and five abstentions, the UN Security Council's intent was to have "an immediate ceasefire in Libya, including an end to the current attacks against civilians, which it said might constitute "crimes against humanity" ...</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hardware_random_number_generator">Hardware random number generator</a></td>
      <td>In computing, a hardware random number generator (HRNG) or true random number generator (TRNG) is a device that generates random numbers from a physical process, rather than by means of an algorithm.  Such devices are often based on microscopic phenomena that generate low-level, statistically random "noise" signals, such as thermal noise, the photoelectric effect, involving a beam splitter, and other quantum phenomena.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tourism_in_Abkhazia">Tourism in Abkhazia</a></td>
      <td>Tourism in Abkhazia is possible under Georgian law for foreigners entering the occupied territory from Georgia, although Georgia cannot assure the safety inside disputed territory.\nHowever, the Abkazian beaches on the Black Sea continue to be accessible for tourists coming from the Russian side of the Abkhazia–Russia border which is not under Georgian control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_license">Medical license</a></td>
      <td>A medical license is an occupational license that permits a person to legally practice medicine. In most countries, a person must have a medical license bestowed either by a specified government-approved professional association or a government agency before he or she can practice medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/EBay">EBay</a></td>
      <td>eBay Inc. ( EE-bay) is an American multinational e-commerce company based in San Jose, California, that facilitates consumer-to-consumer and business-to-consumer sales through its website.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Department_of_Engineering,_University_of_Cambridge">Department of Engineering, University of Cambridge</a></td>
      <td>The University of Cambridge Department of Engineering is the largest department at the University of Cambridge and one of the leading centres of engineering in the world. The department's aim is to address the world's most pressing challenges with science and technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MicroStrategy">MicroStrategy</a></td>
      <td>MicroStrategy Incorporated is an American company that provides business intelligence (BI), mobile software, and cloud-based services.\nFounded in 1989 by Michael J. Saylor, Sanju Bansal, and Thomas Spahr, the firm develops software to analyze internal and external data in order to make business decisions and to develop mobile apps.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_companies_listed_on_the_National_Stock_Exchange_of_India">List of companies listed on the National Stock Exchange of India</a></td>
      <td>This is a list of companies listed on the National Stock Exchange of India (NSE).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Daniel_Lewin">Daniel Lewin</a></td>
      <td>Daniel Mark Lewin (Hebrew: דניאל "דני" מארק לוין; May 14, 1970 – September 11, 2001), sometimes spelled Levin, was an American–Israeli mathematician and entrepreneur who co-founded internet company Akamai Technologies.  A passenger on board American Airlines Flight 11, it is believed that Lewin was stabbed to death by one of the hijackers of that flight, and was the first victim of the September 11th attacks.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tony_Bates">Tony Bates</a></td>
      <td>Anthony J. Bates (born 29 April 1967) is a British born business leader and on 6 May 2019 he was appointed to CEO of Genesys. Bates is the former CEO of Growth at Social Capital.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vitech_Corporation">Vitech Corporation</a></td>
      <td>Vitech Corporation is a systems engineering company responsible for the development and management of two model-based systems engineering tools, CORE and GENESYS. Vitech products have a range of applications and have been used for program management by the U.S. Department of Energy, for railway modernization and waste management in Europe, and for space station and ground-based air defense system development in Australia. In an effort to promote the study of model-based systems engineering, Vitech partners with universities throughout the United States, providing them with its software for instructional and research purposes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cobrowsing">Cobrowsing</a></td>
      <td>Cobrowsing (short for collaborative browsing), in the context of web browsing, is the joint navigation through the World Wide Web by two or more people accessing the same web page at the same time.\n\n\n== History of cobrowsing software ==\nEarly cobrowsing was achieved by local execution of software that had to be installed on the computer of each participant.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bennelong_SwissWellness_Cycling_Team_p/b_Cervelo">Bennelong SwissWellness Cycling Team p/b Cervelo</a></td>
      <td>Bennelong SwissWellness Cycling Team p/b Cervelo (UCI team code: IWS) was an Australian UCI Continental cycling team focusing on road bicycle racing. Based in Tasmania since its establishment in 2000, the team's original title sponsor was a Tasmanian restaurant chain, Praties, but Genesys Wealth Advisers, an Australian financial planning network, has taken over this role in 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Henley_Passport_Index">Henley Passport Index</a></td>
      <td>The Henley Passport Index (abbreviation: HPI) is a global ranking of countries according to the travel freedom enjoyed by of holders of that country's ordinary passport for its citizens. It started in 2006 as Henley &amp; Partners Visa Restrictions Index (HVRI) and was modified and renamed in January 2018.The site provides a ranking for 199 passports of the world according to the number of countries their holders can travel to visa-free.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Steve_Jablonsky">Steve Jablonsky</a></td>
      <td>Steve Jablonsky (born October 9, 1970) is an American composer for film, television and video games, best known for his musical scores in the Transformers film series. Some of his frequent collaboration partners include film directors Michael Bay and Peter Berg, and fellow composer Hans Zimmer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sunpendulum">Sunpendulum</a></td>
      <td>Sunpendulum is an art, science and technology project  devised by Austrian media artist Kurt Hofstetter.\n\n\n== Concept ==\nWatching the sky: "Inplusion" phaseTwelve video cameras called "time-eyes" are connected to the internet in twelve locations in twelve time zones around the Earth, observing the sky twenty four hours per day, continuously creating a hypothetical "sun clock" which spans the planet.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_search_engine">Collaborative search engine</a></td>
      <td>Collaborative search engines (CSE) are Web search engines and enterprise searches within company intranets that let users combine their efforts in information retrieval (IR) activities, share information resources collaboratively using knowledge tags, and allow experts to guide less experienced people through their searches. Collaboration partners do so by providing query terms, collective tagging, adding comments or opinions, rating search results, and links clicked of former (successful) IR activities to users having the same or a related information need.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sexual_surrogate">Sexual surrogate</a></td>
      <td>Sex surrogates, sometimes referred to as surrogate partners, are practitioners trained in addressing issues of intimacy and sexuality. A surrogate partner works in collaboration with a sex therapist to meet the goals of their client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Supply_chain_collaboration">Supply chain collaboration</a></td>
      <td>In supply chain management, supply chain collaboration is defined as two or more autonomous firms working jointly to plan and execute supply chain operations. It can deliver substantial benefits and advantages to collaborators.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Campbell_Collaboration">Campbell Collaboration</a></td>
      <td>The Campbell Collaboration is a nonprofit organization that promotes evidence-based decisions and policy through the production of systematic reviews and other types of evidence synthesis. Campbell is composed of coordinating groups that coordinate the production of systematic reviews and evidence gap maps in the following areas: Business &amp; Management, Climate Solutions, Crime &amp; Justice, Disability, Education, International Development, Knowledge Translation &amp; Implementation, Methods, and Social Welfare.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>HUMAN GENOME SCIENCES INC      ITEM 1A     RISK FACTORS             There are a number of <font color="blue">risk factors</font> that could cause our actual results     to  <font color="blue">differ materially from</font> those that are indicated by forward-looking     statements</td>
    </tr>
    <tr>
      <td>Those factors include, <font color="blue">without limitation</font>, those listed below     and <font color="blue">elsewhere herein</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">commercialize</font> products</font>, we may not be able to     recover our <font color="blue">investment</font> in our <font color="blue">product <font color="blue">development</font></font> and <font color="blue"><font color="blue">manufacturing</font> efforts</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">invested <font color="blue">significant</font></font> time and resources to isolate and study     genes and determine their functions</td>
    </tr>
    <tr>
      <td>We now <font color="blue">devote most</font> of our resources to     developing proteins and <font color="blue">antibodies</font> for the treatment of <font color="blue">human disease</font></td>
    </tr>
    <tr>
      <td>We     are <font color="blue">also devoting</font> substantial resources to the <font color="blue">establishment</font> of our own     <font color="blue">manufacturing</font> <font color="blue">capabilities</font>, both to <font color="blue">support <font color="blue">clinical testing</font></font> and eventual     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We have made and are continuing to make substantial     <font color="blue"><font color="blue">expenditure</font>s</font></td>
    </tr>
    <tr>
      <td>Before we can <font color="blue">commercialize</font> a product, we <font color="blue">must rigorously test</font>     the product in the <font color="blue">laboratory</font> and complete extensive <font color="blue">human studies</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that the costs of testing and <font color="blue">study will yield products</font>     approved  for  marketing  by the FDA or that any <font color="blue">such product</font>s will be     profitable</td>
    </tr>
    <tr>
      <td>We will incur substantial <font color="blue"><font color="blue">additional</font> costs</font> to continue these     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If we are not successful in <font color="blue"><font color="blue">commercializing</font> products</font>, we may be     unable to recover the large <font color="blue">investment</font> we have made in research, <font color="blue">development</font>     and <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td>Because our <font color="blue">product <font color="blue">development</font></font> efforts <font color="blue">depend on</font> new and rapidly     evolving  <font color="blue">technologies</font>,  we cannot be certain that our <font color="blue">efforts will</font> be     successful</td>
    </tr>
    <tr>
      <td>Our work depends on new, rapidly evolving <font color="blue">technologies</font> and on the     <font color="blue">marketability</font> and <font color="blue">profitability</font> of <font color="blue">innovative products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization     </font>involves risks of <font color="blue">failure inherent</font> in the <font color="blue">development</font> of <font color="blue">products based</font>                                         17       _________________________________________________________________           on innovative <font color="blue">technologies</font> and the risks <font color="blue">associated with</font> drug <font color="blue">development</font>     <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>These risks include the <font color="blue">possibility</font> that:         •  these <font color="blue">technologies</font> or any or all of the <font color="blue">products based</font> on these     <font color="blue">technologies</font> will be <font color="blue">in<font color="blue">effective</font></font> or toxic, or <font color="blue">otherwise fail</font> to receive     <font color="blue"><font color="blue">necessary</font> <font color="blue">regulatory</font> clearances</font>;         •  the products, if safe and <font color="blue">effective</font>, will be <font color="blue">difficult</font> to <font color="blue">manufacture</font>     on a large scale or uneconomical to market;          •   <font color="blue">proprietary</font>  rights  of  third  parties  <font color="blue">will prevent us</font> or our     <font color="blue">collaborators</font> from exploiting <font color="blue">technologies</font> or <font color="blue">marketing products</font>; and         •  <font color="blue"><font color="blue">third parties</font> will market</font> superior or <font color="blue">equivalent products</font></td>
    </tr>
    <tr>
      <td>Because we are currently a mid-stage <font color="blue">development</font> company, we cannot be     certain that we can develop our business or achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur losses</font> and we <font color="blue">cannot assure</font> you that we     <font color="blue">will ever become profitable</font></td>
    </tr>
    <tr>
      <td>We are in the mid-stage of <font color="blue">development</font>, and it     will be a number of years, if ever, before we are likely to receive revenue     from  product  sales  or  royalty  payments</td>
    </tr>
    <tr>
      <td>We <font color="blue">will continue</font> to incur     substantial expenses relating to research and <font color="blue">development</font> efforts and human     studies</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of our products requires <font color="blue"><font color="blue">significant</font> further</font>     research, <font color="blue">development</font>, testing and <font color="blue"><font color="blue">regulatory</font> approvals</font></td>
    </tr>
    <tr>
      <td>We may not be able     to  develop products that will be <font color="blue">commercially successful</font> or that will     <font color="blue">generate revenue</font> in excess of the cost of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">continually evaluating</font> our business strategy, and may modify     this strategy in light of <font color="blue">development</font>s in our business and other factors</td>
    </tr>
    <tr>
      <td>In the past, we have redirected the focus of our business from the     <font color="blue">discovery</font> of genes to the <font color="blue">development</font> of medically useful <font color="blue">products based</font> on     those genes</td>
    </tr>
    <tr>
      <td>In this regard, we may, from time to     time, focus our <font color="blue">product <font color="blue">development</font></font> efforts on different products or may     delay or halt the <font color="blue">development</font> of <font color="blue">various products</font></td>
    </tr>
    <tr>
      <td>In addition, as a result     of changes in our strategy, we may also change or refocus our <font color="blue">existing drug</font>     <font color="blue">discovery</font>, <font color="blue">development</font>, <font color="blue">commercialization</font> and <font color="blue">manufacturing</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>could require changes in our <font color="blue">facilities</font> and personnel and the <font color="blue">restructuring</font>     of <font color="blue">various financial arrangements</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that changes will     occur or that any changes that we implement will be successful</td>
    </tr>
    <tr>
      <td>During the past two years, we have sharpened our focus on our most     promising drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have reduced the number of drugs in early     <font color="blue">development</font> and are focusing our <font color="blue">resources on</font> the drugs that address the     <font color="blue">greatest unmet medical</font> needs with substantial <font color="blue">growth potential</font></td>
    </tr>
    <tr>
      <td>In order to     <font color="blue">reduce <font color="blue">significant</font>ly</font> our expenses, and <font color="blue">thus enable us</font> to dedicate more     resources to the <font color="blue">most promising drugs</font>, we have reduced staff, streamlined     <font color="blue">operations</font> and consolidated <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">December </font></font>2005, we <font color="blue">entered into</font> an     <font color="blue">agreement</font> to spin off our <font color="blue">CoGenesys </font>division as an <font color="blue">in<font color="blue">dependent</font> company</font>, in a     <font color="blue">transaction</font>  that  will  be <font color="blue">treated as</font> a sale for <font color="blue"><font color="blue">accounting</font> purposes</font></td>
    </tr>
    <tr>
      <td><font color="blue">CoGenesys </font><font color="blue">will focus on</font> the <font color="blue">development</font> of assets that were unlikely to be     developed by us</td>
    </tr>
    <tr>
      <td>Our ability to discover and develop <font color="blue">new early stage preclinical</font>     <font color="blue"><font color="blue">products will</font> <font color="blue">depend on</font></font> our <font color="blue">internal research capability</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">substantially</font>     reduced our <font color="blue">internal research capability</font> as part of our <font color="blue">restructuring</font> in the     <font color="blue">first quarter</font> of 2004</td>
    </tr>
    <tr>
      <td>Our <font color="blue">internal research capability</font> will be further     <font color="blue">reduced following</font> the spin-off of CoGenesys</td>
    </tr>
    <tr>
      <td>Although we continue to conduct     <font color="blue">discovery</font> and <font color="blue">development</font> efforts on early stage products, our limited     resources for <font color="blue">discovering</font> and developing <font color="blue">early stage preclinical products</font>     may not be sufficient to discover new preclinical drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________           PRODUCT DEVELOPMENT RISKS             Because we have limited experience in developing and <font color="blue">commercializing</font>     products, we may be <font color="blue">unsuccessful</font> in our efforts to do so</td>
    </tr>
    <tr>
      <td>Our ability to develop and <font color="blue"><font color="blue">commercialize</font> products</font> <font color="blue">based on</font> proteins,     <font color="blue">antibodies</font> and other <font color="blue">compounds <font color="blue">will <font color="blue">depend on</font></font></font> our ability to:         •  develop <font color="blue">products internally</font>;         •  complete <font color="blue">laboratory</font> testing and <font color="blue">human studies</font>;         •  obtain and maintain <font color="blue"><font color="blue">necessary</font> <font color="blue">intellectual property</font> rights</font> to our     products;         •  obtain and maintain <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approvals</font> related to the     efficacy and safety of our products;          •   develop and expand production <font color="blue">facilities</font> meeting all <font color="blue">regulatory</font>     <font color="blue">requirements</font> or <font color="blue">enter into</font> <font color="blue">arrangements with <font color="blue">third parties</font></font> to <font color="blue">manufacture</font>     our <font color="blue">products on</font> our behalf; and          •   deploy  sales and <font color="blue">marketing resources <font color="blue">effective</font>ly</font> or <font color="blue">enter into</font>     <font color="blue">arrangements with <font color="blue">third parties</font></font> to provide these functions</td>
    </tr>
    <tr>
      <td>Although we are conducting <font color="blue">human studies</font> with respect to a number of     products, we have limited experience with these <font color="blue">activities</font> and may not be     successful in developing or <font color="blue">commercializing</font> these or other products</td>
    </tr>
    <tr>
      <td>Because <font color="blue">clinical trials</font> for our products are expensive and protracted     and their outcome is uncertain, we <font color="blue">must invest</font> substantial amounts of time     and money that may not <font color="blue">yield viable products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conducting </font><font color="blue">clinical trials</font> is a lengthy, time-consuming and expensive     process</td>
    </tr>
    <tr>
      <td>Before obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font> for the <font color="blue">commercial sale</font> of     any  product, we must demonstrate through <font color="blue">laboratory</font>, animal and human     studies that <font color="blue">such product</font> is <font color="blue">both <font color="blue">effective</font></font> and safe for use in humans</td>
    </tr>
    <tr>
      <td>We     will incur substantial <font color="blue"><font color="blue">additional</font> expense</font> for and devote a <font color="blue">significant</font>     amount of time to these studies</td>
    </tr>
    <tr>
      <td>Before a drug may be marketed in the US, it must be the subject of     <font color="blue">rigorous pre<font color="blue">clinical testing</font></font></td>
    </tr>
    <tr>
      <td>The results of these <font color="blue">studies must</font> be submitted     to the FDA as part of an investigational new drug <font color="blue">application</font>, which is     <font color="blue">reviewed by</font> the FDA before <font color="blue">clinical testing</font> in humans can begin</td>
    </tr>
    <tr>
      <td>The results     of  <font color="blue">preliminary</font>  studies  do not <font color="blue">predict clinical success</font></td>
    </tr>
    <tr>
      <td>A number of     potential  drugs  have  shown  promising  results in <font color="blue">early testing but</font>     <font color="blue">subsequently failed</font> to obtain <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approvals</font></td>
    </tr>
    <tr>
      <td>Data obtained     <font color="blue">from tests</font> are susceptible to varying <font color="blue">interpretation</font>s, which may delay,     limit or prevent <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue"><font color="blue"><font color="blue">authorities</font> may</font> refuse</font> or     <font color="blue">delay approval as</font> a result of many other factors, including changes in     <font color="blue">regulatory</font> policy during the period of <font color="blue">product <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Completion </font>of <font color="blue">clinical trials</font> may take many years</td>
    </tr>
    <tr>
      <td>The length of time     required varies <font color="blue">substantially</font> according to the type, <font color="blue">complexity</font>, novelty and     <font color="blue">intended use</font> of the <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>The FDA monitors the progress of each     phase  of  testing,  and  may  require the modification, suspension or     <font color="blue">termination</font> of a trial if it is determined to <font color="blue">present excessive risks</font> to     patients</td>
    </tr>
    <tr>
      <td>Our rate of <font color="blue">commencement</font> and <font color="blue">completion</font> of <font color="blue">clinical trials</font> may be     <font color="blue">delayed by</font> many factors, including:         •  our <font color="blue">inability</font> to <font color="blue">manufacture</font> sufficient quantities of materials for use     in <font color="blue">clinical trials</font>;         •  <font color="blue">variability</font> in the number and types of <font color="blue">patients available</font> for each     study;          •  <font color="blue">difficult</font>y in maintaining <font color="blue">contact with patients</font> after treatment,     resulting in <font color="blue">incomplete data</font>;         •  <font color="blue">unforeseen safety issues</font> or side effects;         •  poor or <font color="blue">unanticipated <font color="blue">effective</font>ness</font> of <font color="blue">products during</font> the clinical     trials; or         •  <font color="blue">government</font> or <font color="blue">regulatory</font> delays</td>
    </tr>
    <tr>
      <td>To date, data obtained from our <font color="blue">clinical trials</font> are not sufficient to     support an <font color="blue">application</font> for <font color="blue">regulatory</font> approval without further studies</td>
    </tr>
    <tr>
      <td>Studies <font color="blue">conducted by us</font> or <font color="blue">by <font color="blue">third parties</font> on</font> our <font color="blue">behalf may</font> not                                         19       _________________________________________________________________           <font color="blue">demonstrate sufficient <font color="blue">effective</font>ness</font> and safety to obtain the requisite     <font color="blue"><font color="blue">regulatory</font> approvals</font> for these or any other <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Based on the     results of a <font color="blue">human study</font> for a particular <font color="blue">product candidate</font>, <font color="blue">regulatory</font>     <font color="blue"><font color="blue">authorities</font> may</font> not <font color="blue">permit us</font> to undertake any <font color="blue">additional</font> <font color="blue">clinical trials</font>     for  that  product  candidate</td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trial process may also</font> be     <font color="blue">accompanied by</font> substantial delay and expense and there can be no assurance     that the <font color="blue">data generated</font> in these <font color="blue">studies will ultimately</font> be sufficient for     <font color="blue"><font color="blue">marketing approval</font> by</font> the FDA For example, in 2005, we <font color="blue">discontinued</font> our     clinical <font color="blue">development</font> of LymphoRad^131, a <font color="blue">product candidate</font> to treat cancer</td>
    </tr>
    <tr>
      <td>We <font color="blue">face risks</font> in <font color="blue"><font color="blue">connection</font> with</font> our ABthrax product in addition to     risks <font color="blue">generally</font> <font color="blue">associated with</font> drug <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">entry into</font> the <font color="blue">biodefense field with</font> the <font color="blue">development</font> of <font color="blue">ABthrax     </font><font color="blue">presents risks beyond</font> those <font color="blue">associated with</font> the <font color="blue">development</font> of our other     products</td>
    </tr>
    <tr>
      <td>Numerous other companies and <font color="blue">government</font>al agencies, including the     US Army, are known to be developing <font color="blue">biodefense <font color="blue">pharmaceutical</font>s</font> and related     products to <font color="blue">combat anthrax</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">competitors</font> may</font> have financial or other     <font color="blue">resources greater than ours</font>, and may have easier or <font color="blue">preferred access</font> to the     <font color="blue">likely distribution channels</font> for <font color="blue">biodefense products</font></td>
    </tr>
    <tr>
      <td>In addition, since the     <font color="blue">primary purchaser</font> of <font color="blue">biodefense products</font> is the <font color="blue">US Government </font>and its     agencies, the success <font color="blue">of ABthrax </font><font color="blue">will <font color="blue">depend on</font></font> <font color="blue">government</font> spending policies     and <font color="blue">pricing <font color="blue">restrictions</font></font></td>
    </tr>
    <tr>
      <td>The funding of <font color="blue">government</font> biodefense programs is     <font color="blue">dependent</font>, in part, on budgetary constraints, political considerations and     military <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>In the case of the US Government, executive or     <font color="blue">legislative</font>  action  could  attempt  to  <font color="blue">impose production</font> and pricing     <font color="blue">requirements</font> on us</td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> a two-phase contract to supply     ABthrax^tm, a human monoclonal antibody developed for use in the treatment     of <font color="blue">anthrax disease</font>, to the US Government</td>
    </tr>
    <tr>
      <td>Under the first phase of the     contract, we <font color="blue">will supply ten grams</font> <font color="blue">of ABthrax </font>to the US Department of     Health  and  Human Services (HHS) for <font color="blue">comparative</font> in vitro and in vivo     testing</td>
    </tr>
    <tr>
      <td>Under the second phase of the contract, the <font color="blue">US Government </font>has the     option to place an order <font color="blue">within one year</font> for up to 100cmam000 doses of <font color="blue">ABthrax     </font>for the <font color="blue">Strategic National Stockpile</font>, for use in the treatment of anthrax     disease</td>
    </tr>
    <tr>
      <td>We believe that the HHS <font color="blue">comparative</font> testing results, <font color="blue">along with</font>     Human Genome Sciences’ own preclinical and <font color="blue">clinical study</font> results, will form     the basis of the US Government’s <font color="blue">decision process</font> for exercising its     option for <font color="blue"><font color="blue">additional</font> product</font> for the <font color="blue">Strategic National Stockpile</font></td>
    </tr>
    <tr>
      <td>We do     not know whether the <font color="blue">US Government </font><font color="blue">will purchase</font> ABthrax, and if it does,     the timing, extent and amount of such purchases</td>
    </tr>
    <tr>
      <td>If the <font color="blue">US Government </font>    decides  to place an order for ABthrax, we <font color="blue">will continue</font> to <font color="blue">face risks</font>     related to animal and <font color="blue">human testing</font>, to the <font color="blue">manufacture</font> <font color="blue">of ABthrax </font>and to     FDA <font color="blue">concurrence</font> that ABthrax meets the <font color="blue">requirements</font> of the contract</td>
    </tr>
    <tr>
      <td>If we     are unable to meet the product <font color="blue">requirements</font> <font color="blue">associated with</font> this contract,     the <font color="blue">US Government </font>will not be required to <font color="blue">reimburse us</font> for the costs     incurred or to purchase any <font color="blue">product pursuant</font> to that order</td>
    </tr>
    <tr>
      <td>Because neither we nor any of our <font color="blue"><font color="blue">collaboration</font> partners</font> have received     <font color="blue">marketing approval</font> for any <font color="blue">product candidate</font> resulting from our research and     <font color="blue">development</font> efforts, and because we may never be able to obtain any such     approval, it is possible that we may not be able to generate any product     revenue</td>
    </tr>
    <tr>
      <td>Neither we nor any of our <font color="blue"><font color="blue">collaboration</font> partners</font> have completed     <font color="blue">development</font> of any <font color="blue">product <font color="blue">based on</font></font> our <font color="blue">genomics research</font></td>
    </tr>
    <tr>
      <td>It is possible     that we will not receive FDA <font color="blue">marketing approval</font> for any of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>a number of our <font color="blue">potential products</font> have entered     clinical  trials, we <font color="blue">cannot assure</font> you that any of these <font color="blue">products will</font>     receive  marketing  approval</td>
    </tr>
    <tr>
      <td>All the products being developed by our     <font color="blue">collaboration</font>  partners  will  also  require  <font color="blue">additional</font>  research and     <font color="blue">development</font>,  extensive  preclinical  studies  and <font color="blue">clinical trials</font> and     <font color="blue">regulatory</font> approval prior to any <font color="blue">commercial sale</font>s</td>
    </tr>
    <tr>
      <td>In some cases, the length     of time that it takes for our <font color="blue"><font color="blue">collaboration</font> partners</font> to achieve various     <font color="blue">regulatory</font> approval milestones may affect the payments that we are eligible     to receive under our <font color="blue">collaboration</font> <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>We and our <font color="blue">collaboration</font>     <font color="blue">partners may</font> need to <font color="blue">successfully</font> address a number of technical <font color="blue">challenges</font>     in order to complete <font color="blue">development</font> of our products</td>
    </tr>
    <tr>
      <td>Moreover, these products     may  not  be  <font color="blue">effective</font>  in  treating any disease or may prove to have     undesirable or unintended side effects, toxicities or other <font color="blue">characteristics</font>     that may preclude our obtaining <font color="blue">regulatory</font> approval or prevent or limit     <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________           RISK FROM COLLABORATION RELATIONSHIPS AND STRATEGIC ACQUISITIONS             Our plan to use <font color="blue">collaboration</font>s to leverage our <font color="blue">capabilities</font> and to     grow  in part through the <font color="blue">strategic <font color="blue">acquisition</font></font> of other companies and     <font color="blue">technologies</font>  may  not be successful if we are unable to integrate our     partners’ <font color="blue">capabilities</font> or the acquired <font color="blue">companies with</font> our <font color="blue">operations</font> or if     our partners’ <font color="blue">capabilities</font> do not meet our <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>As part of our strategy, we intend to continue to <font color="blue">evaluate strategic</font>     <font color="blue">partnership <font color="blue">opportunities</font></font> and consider acquiring complementary <font color="blue">technologies</font>     and  <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>In  order for our future <font color="blue">collaboration</font> efforts to be     successful, we must first identify partners whose <font color="blue">capabilities</font> complement     and <font color="blue">integrate well with ours</font></td>
    </tr>
    <tr>
      <td><font color="blue">Technologies </font>to which we gain access may prove     <font color="blue">in<font color="blue">effective</font></font> or unsafe</td>
    </tr>
    <tr>
      <td>Our current <font color="blue">agreement</font>s that <font color="blue">grant us access</font> to such     <font color="blue"><font color="blue">technology</font> may</font> expire and may not be renewable</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">partners may</font> prove</font>     <font color="blue">difficult</font> to work with or <font color="blue">less skilled than</font> we <font color="blue">originally</font> expected</td>
    </tr>
    <tr>
      <td>In     addition, any <font color="blue">past collaborative successes</font> are <font color="blue">no indication</font> of potential     future  success</td>
    </tr>
    <tr>
      <td>In  order  to achieve the anticipated benefits of an     <font color="blue">acquisition</font>, we <font color="blue">must integrate</font> the acquired company’s business, <font color="blue">technology</font>     and  employees  in  an  <font color="blue">efficient</font> and <font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>The successful     <font color="blue">combination</font> of companies in a rapidly changing bio<font color="blue">technology</font> and genomics     <font color="blue">industry may</font> be more <font color="blue">difficult</font> to accomplish than in other <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">combination</font> of two companies requires, among other things, <font color="blue">integration</font> of     the companies’ respective <font color="blue">technologies</font> and research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that this <font color="blue"><font color="blue">integration</font> will</font> be accomplished smoothly or     <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">difficult</font>ies of <font color="blue">integration</font> are <font color="blue">increased by</font> the <font color="blue">necessity</font>     of  coordinating geographically separated organizations and <font color="blue">addressing</font>     <font color="blue">possible differences</font> in <font color="blue">corporate cultures</font> and <font color="blue"><font color="blue">management</font> philosophies</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">integration</font> of certain <font color="blue">operations</font> will require the <font color="blue">dedication</font> of <font color="blue">management</font>     resources  that <font color="blue">may temporarily distract attention from</font> the day-to-day     <font color="blue">operations</font> of the <font color="blue">combined companies</font></td>
    </tr>
    <tr>
      <td>The business of the <font color="blue">combined companies</font>     may also be <font color="blue">disrupted by employee retention uncertainty</font> and lack of focus     during <font color="blue">integration</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> of <font color="blue">management</font> to integrate <font color="blue">successfully</font>     the <font color="blue">operations</font> of the two companies, in particular, to integrate and retain     <font color="blue">key scientific personnel</font>, or the <font color="blue">inability</font> to integrate <font color="blue">successfully</font> two     <font color="blue">technology</font> platforms, could have a material adverse effect on our business,     results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although GSK </font>has agreed to be our partner in the <font color="blue">development</font> and     <font color="blue">commercialization</font>  of  LymphoStat-B  and HGS-ETR1, we may be unable to     negotiate an appropriate co-<font color="blue">development</font> and co-marketing <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>As  part  of  our  June  1996  <font color="blue">agreement</font> with GSK, we granted a     50/50 co-<font color="blue">development</font> and <font color="blue">commercialization</font> option to GSK for certain human     <font color="blue">therapeutic</font> products that <font color="blue">successfully</font> complete Phase 2a <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>On     July 7, 2005, we announced that GSK had exercised its option to develop and     <font color="blue">commercialize</font> LymphoStat-B (belimumab) jointly with us and on August 18,     2005,  we  announced  that GSK had exercised its option to develop and     <font color="blue">commercialize</font> HGS-ETR1 (mapatumumab) jointly with us</td>
    </tr>
    <tr>
      <td>Under the terms of the     1996 <font color="blue">agreement</font>, GSK and we will share equally in Phase 34 <font color="blue">development</font> costs     of these products, and will share equally in sales and <font color="blue">marketing expenses</font>     and  profits  of  any  <font color="blue">such product</font> that is <font color="blue">commercialize</font>d pursuant to     co-<font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">agreement</font>s, the <font color="blue">remaining terms</font> of     which are subject to <font color="blue">negotiation</font></td>
    </tr>
    <tr>
      <td>We do not know if we will be successful in     negotiating such <font color="blue">agreement</font>s, and if we are <font color="blue">unsuccessful</font>, we do not know if,     and how, GSK and we will <font color="blue">collaborate</font> on these products</td>
    </tr>
    <tr>
      <td>If we complete the spin-off of our <font color="blue">CoGenesys </font>division, our ability to     receive <font color="blue">revenues from</font> the assets transferred with <font color="blue">CoGenesys </font><font color="blue">will <font color="blue">depend on</font></font>     CoGenesys’ ability to develop and <font color="blue">commercialize</font> those assets</td>
    </tr>
    <tr>
      <td>The spin-off of our <font color="blue">CoGenesys </font>division is <font color="blue">contingent on</font> the <font color="blue">receipt by</font>     <font color="blue">CoGenesys </font>of third party financing</td>
    </tr>
    <tr>
      <td>As a result, we <font color="blue">cannot assure</font> you that     the <font color="blue">transaction</font>, which will be <font color="blue">treated as</font> a sale for <font color="blue"><font color="blue">accounting</font> purposes</font>,     will be completed as currently structured</td>
    </tr>
    <tr>
      <td>If the <font color="blue">transaction</font> is completed,     we <font color="blue">will <font color="blue">depend on</font></font> <font color="blue">CoGenesys </font>to develop and <font color="blue">commercialize</font> those assets</td>
    </tr>
    <tr>
      <td>If     <font color="blue">CoGenesys </font>is not successful in its efforts, we may not receive any revenue     from the <font color="blue">development</font> of <font color="blue">CoGenesys </font>assets</td>
    </tr>
    <tr>
      <td><font color="blue">CoGenesys </font>will require <font color="blue">significant</font>     third  party  financing,  which  may  be unavailable</td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue">relationship with</font> <font color="blue">CoGenesys </font>will be subject to the risks and <font color="blue">uncertainties</font>     inherent in our other <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________                 Because we <font color="blue">depend on</font> our <font color="blue"><font color="blue">collaboration</font> partners</font> for revenue, we may     not  become  profitable  if  we  cannot  increase the <font color="blue">revenue from</font> our     <font color="blue"><font color="blue">collaboration</font> partners</font> or other sources</td>
    </tr>
    <tr>
      <td>We have received all of our <font color="blue">revenue from</font> payments made under our     <font color="blue">collaboration</font> <font color="blue">agreement</font>s with GSK and, to a <font color="blue">lesser extent</font>, other <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>The initial research term <font color="blue">of the GSK </font><font color="blue">collaboration</font> <font color="blue">agreement</font> and many of our     other <font color="blue">collaboration</font> <font color="blue">agreement</font>s expired in 2001</td>
    </tr>
    <tr>
      <td>None of these <font color="blue">collaboration</font>     <font color="blue">agreement</font>s  was  renewed</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">enter into</font> <font color="blue">additional</font>     <font color="blue">collaboration</font> <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>We are entitled to <font color="blue">certain milestone</font> and royalty     payments from the existing <font color="blue">collaborators</font>, but may not receive payments if     our <font color="blue"><font color="blue">collaborators</font> fail</font> to:         •  develop <font color="blue">marketable products</font>;         •  obtain <font color="blue"><font color="blue">regulatory</font> approvals</font> for products; or         •  <font color="blue">successfully</font> market <font color="blue">products based</font> on our research</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">circumstances could</font> arise <font color="blue">under which one</font> or more of our     <font color="blue"><font color="blue">collaboration</font> partners</font> may allege that we breached our <font color="blue">agreement</font> with them     and,  <font color="blue">accordingly</font>,  seek  to  terminate our <font color="blue">relationship with</font> them</td>
    </tr>
    <tr>
      <td>If     successful, this <font color="blue">could adversely affect</font> our ability to <font color="blue">commercialize</font> our     products and harm our business</td>
    </tr>
    <tr>
      <td>If one of our <font color="blue"><font color="blue">collaborators</font> pursues</font> a product that <font color="blue">competes with</font> our     products, there could be a conflict of interest and we may not receive the     milestone or <font color="blue">royalty payments</font> that we expect</td>
    </tr>
    <tr>
      <td>Each of our <font color="blue">collaborators</font> is developing a variety of products, some     with other partners</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> may pursue existing or <font color="blue">alternative</font>     <font color="blue">technologies</font> to develop <font color="blue">drugs targeted at</font> the <font color="blue">same diseases instead</font> of using     our licensed <font color="blue">technology</font> to develop products in <font color="blue">collaboration</font> with us</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">collaborators</font> may also develop products that are similar to or <font color="blue">compete with</font>     products they are developing in <font color="blue">collaboration</font> with us</td>
    </tr>
    <tr>
      <td>If our <font color="blue">collaborators</font>     pursue these other products instead of our products, we may not receive     milestone or <font color="blue">royalty payments</font></td>
    </tr>
    <tr>
      <td>FINANCIAL AND MARKET RISKS             Because of our substantial indebtedness, we may be unable to adjust     our strategy to meet changing <font color="blue">conditions</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had long-term <font color="blue">obligation</font>s of <font color="blue">approximately</font>     dlra510dtta0 million</td>
    </tr>
    <tr>
      <td>We also had a <font color="blue">future guarantee <font color="blue">obligation</font></font> of dlra200dtta0 million     under the <font color="blue">current terms</font> of <font color="blue">one <font color="blue">facility</font> lease</font></td>
    </tr>
    <tr>
      <td>Our substantial debt and     future guarantee will have <font color="blue">several important consequences</font> for our future     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For instance:         •  payments of <font color="blue">interest on</font>, and principal of, our <font color="blue">indebtedness will</font> be     substantial, and may exceed then current revenues and <font color="blue">available cash</font>;         •  a <font color="blue">default under</font> the terms of these <font color="blue">existing <font color="blue">obligation</font>s could</font> result in     the <font color="blue">termination</font> of <font color="blue">certain leases</font> and the <font color="blue">acceleration</font> of the maturity of     our other <font color="blue">financial <font color="blue">obligation</font>s</font>;         •  we may be unable to obtain <font color="blue">additional</font> future financing for continued     <font color="blue">clinical trials</font>, capital <font color="blue"><font color="blue">expenditure</font>s</font>, <font color="blue">acquisition</font>s or <font color="blue">general corporate</font>     purposes;         •  we may be unable to withstand changing <font color="blue">competitive</font> pressures, economic     <font color="blue">conditions</font> and <font color="blue">government</font>al <font color="blue">regulations</font>; and         •  we may be unable to make <font color="blue">acquisition</font>s or otherwise take advantage of     <font color="blue">significant</font> business <font color="blue">opportunities</font> that may arise</td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> an off-<font color="blue">balance sheet</font> <font color="blue">facility</font> lease arrangement     that <font color="blue">constitutes</font> a <font color="blue">significant</font> financial <font color="blue">obligation</font> and <font color="blue">possible risks</font> to     our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>In the second quarter of 2003, we <font color="blue">entered into</font> a <font color="blue">facility</font> lease for     our  research  and  <font color="blue">development</font>  and  <font color="blue">administrative</font>  <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Under     US <font color="blue">generally</font> accepted <font color="blue">accounting</font> principles, this lease was <font color="blue">treated as</font> an     operating lease</td>
    </tr>
    <tr>
      <td>In the event we default on our <font color="blue">obligation</font> under the lease,     we may be responsible for up to dlra200dtta0 million of the cost of the <font color="blue">facility</font>     because of a guarantee we made in <font color="blue"><font color="blue">connection</font> with</font> the lease</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>                                    22       _________________________________________________________________           <font color="blue">obligation</font> is not required to be <font color="blue">reflected as</font> a <font color="blue">liability on</font> our balance     sheet, but is described in footnotes to our <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>We are     required to <font color="blue">pledge marketable securities as security</font> for our <font color="blue">obligation</font>     under the lease and the related <font color="blue">documents</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we     included <font color="blue">approximately</font> dlra220dtta2 million of restricted <font color="blue">investment</font>s on our     <font color="blue">balance sheet</font>, of which <font color="blue">approximately</font> dlra207dtta2 million was held <font color="blue">as restricted</font>     <font color="blue">investment</font>s providing collateral for our <font color="blue">obligation</font> with respect to this     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>If the value of our pledged <font color="blue">investment</font>s declines, because of an     increase in <font color="blue">interest rates</font> or otherwise, we would need to pledge <font color="blue">additional</font>     <font color="blue">investment</font>s, which would further reduce our working capital</td>
    </tr>
    <tr>
      <td>The rent under     this lease is <font color="blue">based on</font> a floating interest rate, but the <font color="blue">lessors at</font> our     request can lock in a fixed <font color="blue">interest rate at</font> an <font color="blue">interest rate premium</font></td>
    </tr>
    <tr>
      <td>To     the extent the lessors do not lock in a fixed interest rate, if interest     <font color="blue">rates increase</font>, our rent <font color="blue">obligation</font> would also increase</td>
    </tr>
    <tr>
      <td>The lease has a     term of <font color="blue">seven years</font></td>
    </tr>
    <tr>
      <td>If we desire to remain in the <font color="blue">facility</font> upon lease     expiration, we would need to refinance or buy the <font color="blue">facility</font> at the financed     project cost</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">refinancing will</font> be <font color="blue">available on</font>     <font color="blue">comparable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>Further, in the event the <font color="blue">facility</font> is sold, we     have a guarantee <font color="blue">obligation</font> which makes <font color="blue">us responsible</font> to the extent that     the value of the <font color="blue">facility</font> is less than the financed project cost and which     will reach a maximum guarantee <font color="blue">obligation</font> of <font color="blue">approximately</font> dlra175dtta5 million if     the  value  of the <font color="blue">facility</font> declined below <font color="blue">approximately</font> 12dtta25prca of the     financed project cost</td>
    </tr>
    <tr>
      <td>While we believe that this <font color="blue">lease provides</font> a useful     financing mechanism for the <font color="blue">facility</font>, adverse public perception of such     <font color="blue">lease arrangements</font> and the <font color="blue">associated risks may</font> cause our stock price to     decline</td>
    </tr>
    <tr>
      <td>To pursue our current business strategy and continue developing our     products,  we are likely to need substantial <font color="blue">additional</font> funding in the     future</td>
    </tr>
    <tr>
      <td>If we do not obtain this <font color="blue">funding on</font> acceptable terms, we may not be     able to continue to grow our business and <font color="blue">generate enough revenue</font> to recover     our <font color="blue">investment</font> in our <font color="blue">product <font color="blue">development</font></font> effort</td>
    </tr>
    <tr>
      <td>Since inception, we have expended, and <font color="blue">will continue</font> to expend,     substantial funds to continue our research and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We are     likely to need <font color="blue">additional</font> financing to fund our operating expenses and     capital <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In the third quarter of 2005, we issued dlra230dtta0 million     in 2^1/4prca convertible subordinated notes due 2012 and in the <font color="blue">fourth quarter</font>     of 2005, we repurchased all of the <font color="blue">remaining outstanding subordinated</font> notes     due 2007</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">additional</font> financing on acceptable     terms</td>
    </tr>
    <tr>
      <td>If  we  raise  <font color="blue">additional</font>  <font color="blue">funds by issuing equity securities</font>,     equity-linked securities or <font color="blue">debt securities</font>, the <font color="blue">new equity securities may</font>     dilute the interests of our <font color="blue">existing <font color="blue">stockholders</font></font> or the new <font color="blue">debt securities</font>     <font color="blue">may contain restrictive financial covenants</font></td>
    </tr>
    <tr>
      <td>Our  need  for  <font color="blue">additional</font> funding <font color="blue">will <font color="blue">depend on</font></font> many factors,     including, <font color="blue">without limitation</font>:         •  the amount of revenue, if any, that we are able to obtain from our     <font color="blue">collaboration</font>s, any <font color="blue">approved products</font>, and the time and costs required to     achieve those revenues;         •  the timing, scope and results of <font color="blue">preclinical studies</font> and clinical     trials;         •  the size and <font color="blue">complexity</font> of our <font color="blue">development</font> programs;         •  the time and <font color="blue">costs involved</font> in obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font>;         •  the cost of launching our products;          •   the costs of <font color="blue">commercializing</font> our products, including marketing,     promotional and <font color="blue">sales costs</font>;         •  our ability to establish and maintain <font color="blue"><font color="blue">collaboration</font> partners</font>hips;         •  <font color="blue">competing technological</font> and market <font color="blue">development</font>s;         •  the <font color="blue">costs involved</font> in filing, prosecuting and <font color="blue">enforcing patent</font> claims;     and         •  scientific progress in our research and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>If we are unable to raise <font color="blue">additional</font> funds, we may, among other     things:         •  delay, scale back or eliminate some or all of our research and     <font color="blue">development</font> programs;         •  delay, scale back or eliminate some or all of our <font color="blue">commercialization</font>     <font color="blue">activities</font>;                                         23       _________________________________________________________________             •  <font color="blue">lose rights under existing licenses</font>;         •  <font color="blue">relinquish</font> more of, or all of, our rights to product <font color="blue">candidates</font> on less     favorable terms than we <font color="blue">would otherwise seek</font>; and         •  be unable to operate as a going concern</td>
    </tr>
    <tr>
      <td>Our <font color="blue">insurance policies</font> are expensive and <font color="blue">protect us only from</font> some     business  risks, which will leave us exposed to <font color="blue">significant</font>, uninsured     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>We do not carry insurance for all <font color="blue">categories</font> of risk that our business     <font color="blue">may encounter</font></td>
    </tr>
    <tr>
      <td>We currently maintain general liability, property, auto,     workers’ compensation, products liability and <font color="blue">directors</font>’ and officers’     <font color="blue">insurance policies</font></td>
    </tr>
    <tr>
      <td>We do not know, however, if we will be able to maintain     existing  <font color="blue">insurance with adequate levels</font> of coverage</td>
    </tr>
    <tr>
      <td>For example, the     premiums for our <font color="blue">directors</font>’ and officers’ insurance policy have increased     over time, and this type of <font color="blue">insurance may</font> not be <font color="blue">available on</font> acceptable     terms or at all in the future</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> uninsured liability may     require us to pay substantial amounts, which would adversely affect our cash     position and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>INTELLECTUAL PROPERTY RISKS              If <font color="blue">patent laws</font> or the <font color="blue">interpretation</font> of <font color="blue">patent laws</font> change, our     <font color="blue"><font color="blue">competitors</font> may</font> be able to develop and <font color="blue">commercialize</font> our <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td><font color="blue">Important </font><font color="blue">legal issues remain</font> to be <font color="blue">resolved as</font> to the extent and     scope  of  available  <font color="blue">patent protection</font> for bio<font color="blue">technology</font> products and     processes <font color="blue">in the US </font>and other <font color="blue">important markets outside</font> the US, such as     <font color="blue">Europe and Japan</font></td>
    </tr>
    <tr>
      <td>Foreign <font color="blue">markets may</font> not provide the same level of patent     protection  as  provided  under the US <font color="blue">patent system</font></td>
    </tr>
    <tr>
      <td>We expect that     <font color="blue">litigation</font>  or  <font color="blue">administrative</font> <font color="blue">proceedings</font> will likely be <font color="blue">necessary</font> to     determine the validity and scope of certain of our and others’ <font color="blue">proprietary</font>     rights</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently involved</font> in a number of <font color="blue">administrative</font> <font color="blue">proceedings</font>     relating to the scope of protection of our patents and those of others</td>
    </tr>
    <tr>
      <td>Any     such <font color="blue">litigation</font> or <font color="blue">proceeding may</font> result in a <font color="blue">significant</font> commitment of     resources  in  the  future and <font color="blue">could force us</font> to do one or more of the     following: cease selling or using any of our products that <font color="blue">incorporate</font> the     challenged <font color="blue">intellectual property</font>, which would adversely affect our revenue;     obtain a <font color="blue">license from</font> the holder of the <font color="blue">intellectual property</font> right alleged     to have been infringed, which license may not be <font color="blue">available on</font> reasonable     terms,  if  at  all; and redesign our products to <font color="blue">avoid infringing</font> the     <font color="blue">intellectual property</font> rights of <font color="blue">third parties</font>, which may be time-consuming     or impossible to do</td>
    </tr>
    <tr>
      <td>In addition, changes in, or different <font color="blue">interpretation</font>s     of, <font color="blue">patent laws</font> <font color="blue">in the US </font>and other <font color="blue">countries may</font> result in <font color="blue">patent laws</font>     that <font color="blue">allow others</font> to use our <font color="blue">discoveries</font> or develop and <font color="blue">commercialize</font> our     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that the patents we obtain or the unpatented     <font color="blue">technology</font> we hold will afford us <font color="blue">significant</font> commercial protection</td>
    </tr>
    <tr>
      <td>If our patent <font color="blue">application</font>s do not result in <font color="blue">issued patents</font>, our     <font color="blue">competitors</font>  may obtain rights to and <font color="blue">commercialize</font> the <font color="blue">discoveries</font> we     attempted to patent</td>
    </tr>
    <tr>
      <td>Our pending patent <font color="blue">application</font>s, including those covering full-length     genes and their corresponding proteins, may not result in the issuance of     any patents</td>
    </tr>
    <tr>
      <td>Our <font color="blue">application</font>s may not be sufficient to meet the statutory     <font color="blue">requirements</font>  for  <font color="blue">patentability</font> in all cases or may be the subject of     <font color="blue">interference</font>  <font color="blue">proceedings</font>  by  the  <font color="blue">Patent and Trademark Office</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">proceedings</font> determine the priority of <font color="blue">inventions</font> and, thus, the right to a     patent  for  <font color="blue">technology</font>  in  the  US We are involved in <font color="blue">interference</font>     <font color="blue">proceedings</font>,  including <font color="blue">proceedings</font> related to <font color="blue">products based</font> on TRAIL     Receptor 2 (such as HGS-ETR2 and HGS-TR2J) and may be involved in other     <font color="blue">interference</font> <font color="blue">proceedings</font> in the future</td>
    </tr>
    <tr>
      <td>We are <font color="blue">also involved</font> in opposition     <font color="blue">proceedings</font> in <font color="blue"><font color="blue">connection</font> with</font> foreign patent filings, including <font color="blue">oppositions</font>     related  to  <font color="blue">products based</font> on BLyS (such as LymphoStat-B), and may be     involved in other opposition <font color="blue">proceedings</font> in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that we will be successful in any of these <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>If others file patent <font color="blue">application</font>s or obtain patents similar to ours,     then the <font color="blue">Patent and Trademark Office</font> may deny our patent <font color="blue">application</font>s, or     <font color="blue">others may restrict</font> the use of our <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>We are aware that others, including <font color="blue">universities</font> and companies working     in  the  bio<font color="blue">technology</font>  and  <font color="blue">pharmaceutical</font>  fields, have <font color="blue">filed patent</font>     <font color="blue">application</font>s and have <font color="blue">been granted patents</font> <font color="blue">in the US </font>and in other                                         24       _________________________________________________________________           countries that cover subject matter <font color="blue">potentially useful</font> or <font color="blue">necessary</font> to our     business</td>
    </tr>
    <tr>
      <td>Some of these patents and patent <font color="blue">application</font>s claim only specific     products or methods of making products, while others claim more general     processes or <font color="blue">techniques</font> useful in the <font color="blue">discovery</font> and <font color="blue">manufacture</font> of a variety     of products</td>
    </tr>
    <tr>
      <td>The risk of <font color="blue">third parties</font> obtaining <font color="blue">additional</font> patents and     filing patent <font color="blue">application</font>s <font color="blue">will continue</font> to <font color="blue">increase as</font> the bio<font color="blue">technology</font>     <font color="blue">industry expands</font></td>
    </tr>
    <tr>
      <td>We cannot predict the <font color="blue">ultimate scope</font> and validity of     <font color="blue">existing patents</font> and patents that may be granted to <font color="blue">third parties</font>, nor can     we predict the extent to which we may wish or be required to obtain licenses     to <font color="blue">such patents</font>, or the <font color="blue">availability</font> and cost of acquiring <font color="blue">such licenses</font></td>
    </tr>
    <tr>
      <td>To     the extent that licenses are required, the owners of the <font color="blue">patents could bring</font>     <font color="blue">legal actions against us</font> to claim damages or to stop our <font color="blue">manufacturing</font> and     marketing of the <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>We believe that there <font color="blue">will continue</font> to     be  <font color="blue">significant</font>  <font color="blue">litigation</font> in our industry regarding patent and other     <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>If we <font color="blue">become involved</font> in <font color="blue">litigation</font>, it could     consume a substantial portion of our resources</td>
    </tr>
    <tr>
      <td>Because <font color="blue">issued patents</font> may not <font color="blue">fully protect</font> our <font color="blue">discoveries</font>, our     <font color="blue"><font color="blue">competitors</font> may</font> be able to <font color="blue"><font color="blue">commercialize</font> products</font> similar to those covered     by our <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>Issued <font color="blue">patents may</font> not <font color="blue">provide commercially meaningful protection</font>     against <font color="blue">competitors</font> and may not <font color="blue">provide us with <font color="blue">competitive</font> advantages</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue"><font color="blue">parties may</font> challenge</font> our patents or <font color="blue">design around</font> our <font color="blue">issued patents</font>     or develop products providing effects similar to our products</td>
    </tr>
    <tr>
      <td>In addition,     others may discover uses for genes, proteins or <font color="blue">antibodies</font> other than those     uses  covered  in  our patents, and these other uses may be <font color="blue">separately</font>     patentable</td>
    </tr>
    <tr>
      <td>The holder of a patent covering the use of a gene, protein or     antibody for which we have a patent claim <font color="blue">could exclude us from selling</font> a     product for a <font color="blue">use covered by</font> its patent</td>
    </tr>
    <tr>
      <td>We rely on our <font color="blue"><font color="blue">collaboration</font> partners</font> to seek <font color="blue">patent protection</font> for     the products they develop <font color="blue">based on</font> our research</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our <font color="blue">future revenue may</font> be <font color="blue">derived from</font>     <font color="blue">royalty payments</font> from our <font color="blue"><font color="blue">collaboration</font> partners</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">partners face</font> the     same <font color="blue">patent protection</font> issues that we and other bio<font color="blue">technology</font> firms face</td>
    </tr>
    <tr>
      <td>As     a  result,  we  cannot  assure  you  that any product developed by our     <font color="blue"><font color="blue">collaboration</font> partners</font> will be patentable, and therefore, <font color="blue">revenue from</font> any     <font color="blue">such product</font> may be limited, which would reduce the amount of any royalty     payments</td>
    </tr>
    <tr>
      <td>We  also  rely on our <font color="blue"><font color="blue">collaboration</font> partners</font> to <font color="blue">effective</font>ly     prosecute their patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Their failure to obtain or protect     <font color="blue">necessary</font> patents could also result in a loss of <font color="blue">royalty revenue</font> to us</td>
    </tr>
    <tr>
      <td>If we are unable to protect our <font color="blue">trade secrets</font>, others may be able to     use our secrets to compete more <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>We may not be able to meaning<font color="blue">fully protect</font> our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We rely     <font color="blue">on trade secret protection</font> to protect our <font color="blue">confidential</font> and <font color="blue">proprietary</font>     information</td>
    </tr>
    <tr>
      <td>We believe we have acquired or developed <font color="blue">proprietary</font> procedures     and materials for the production of proteins</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">sought patent</font>     protection for these procedures</td>
    </tr>
    <tr>
      <td>While we have <font color="blue">entered into</font> <font color="blue">confidential</font>ity     <font color="blue">agreement</font>s with employees and academic <font color="blue">collaborators</font>, we may not be able to     prevent  their  <font color="blue">disclosure</font>  of  these  data  or  materials</td>
    </tr>
    <tr>
      <td>Others may     in<font color="blue">dependent</font>ly develop <font color="blue">substantially</font> equivalent information and processes</td>
    </tr>
    <tr>
      <td>REGULATORY RISKS             Because we are subject to extensive changing <font color="blue">government</font> <font color="blue">regulatory</font>     <font color="blue">requirements</font>, we may be unable to obtain <font color="blue">government</font> approval of our products     in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Regulations <font color="blue">in the US </font>and other countries have a <font color="blue">significant</font> impact     on our research, <font color="blue">product <font color="blue">development</font></font> and <font color="blue">manufacturing</font> <font color="blue">activities</font> and will     be  a  <font color="blue">significant</font> factor in the marketing of our products</td>
    </tr>
    <tr>
      <td>All of our     <font color="blue">products will</font> require <font color="blue">regulatory</font> approval prior to <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In     particular, our products are subject to <font color="blue">rigorous preclinical</font> and clinical     testing and other premarket approval <font color="blue">requirements</font> by the FDA and similar     <font color="blue">regulatory</font> <font color="blue">authorities</font> in other countries, such as in <font color="blue">Europe and Japan</font></td>
    </tr>
    <tr>
      <td>Various statutes and <font color="blue"><font color="blue">regulations</font> also govern</font> or influence the <font color="blue">manufacturing</font>,     safety, labeling, storage, record keeping and marketing of our products</td>
    </tr>
    <tr>
      <td>The     <font color="blue">lengthy process</font> of seeking these approvals, and the <font color="blue">subsequent compliance</font>     with  applicable  statutes and <font color="blue">regulations</font>, require the <font color="blue">expenditure</font> of     substantial  resources</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">failure by us</font> to obtain, or any delay in     obtaining,  <font color="blue"><font color="blue">regulatory</font> approvals</font> could materially adversely affect our     ability to <font color="blue">commercialize</font> our products in a <font color="blue">timely manner</font>, or at all</td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________                 <font color="blue">Marketing Approvals</font></td>
    </tr>
    <tr>
      <td>Before a product can be marketed and sold, the     results of the preclinical and <font color="blue">clinical testing</font> must be submitted to the FDA     for approval</td>
    </tr>
    <tr>
      <td>This <font color="blue">submission will</font> be either a new drug <font color="blue">application</font> or a     biologic license <font color="blue">application</font>, depending on the type of drug</td>
    </tr>
    <tr>
      <td>In responding     to a new drug <font color="blue">application</font> or a biologic license <font color="blue">application</font>, the FDA may     grant  marketing  approval, request <font color="blue">additional</font> information or deny the     <font color="blue">application</font>  if it determines that the <font color="blue">application</font> does not provide an     <font color="blue">adequate basis</font> for approval</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any approval required     by the FDA will be obtained on a <font color="blue">timely basis</font>, or at all</td>
    </tr>
    <tr>
      <td>In addition, the FDA may condition <font color="blue">marketing approval</font> on the conduct     of specific post-marketing studies to <font color="blue">further evaluate safety</font> and efficacy</td>
    </tr>
    <tr>
      <td>Rigorous and extensive FDA regulation of <font color="blue">pharmaceutical</font> products continues     after approval, particularly with respect to <font color="blue">compliance with current</font> good     <font color="blue">manufacturing</font>  practices,  or  cGMPs,  reporting  of  <font color="blue">adverse effects</font>,     <font color="blue">advertising</font>,  promotion and marketing</td>
    </tr>
    <tr>
      <td><font color="blue">Discovery </font>of <font color="blue">previously</font> unknown     problems or failure to comply with the applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>     may result in <font color="blue">restrictions</font> on the marketing of a product or withdrawal of     the <font color="blue">product from</font> the <font color="blue">market as well as possible civil</font> or <font color="blue">criminal sanctions</font>,     any of <font color="blue">which could materially adversely affect</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Foreign Regulation</font></td>
    </tr>
    <tr>
      <td>We must obtain <font color="blue">regulatory</font> approval by <font color="blue">government</font>al     agencies in other countries prior to <font color="blue">commercialization</font> of our products in     those countries</td>
    </tr>
    <tr>
      <td>Foreign <font color="blue">regulatory</font> systems may be just as rigorous, costly     and <font color="blue">uncertain as</font> <font color="blue">in the US </font>            Because we are subject to environmental, health and <font color="blue">safety laws</font>, we     may be unable to conduct our business in the <font color="blue">most advantageous manner</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">various laws</font> and <font color="blue">regulations</font> relating to safe     working <font color="blue">conditions</font>, <font color="blue">laboratory</font> and <font color="blue">manufacturing</font> practices, the <font color="blue">experimental</font>     use  of  animals, emissions and wastewater discharges, and the use and     disposal of <font color="blue">hazardous</font> or potentially <font color="blue">hazardous</font> substances used in <font color="blue">connection</font>     with our research, including <font color="blue">radioactive compounds</font> and <font color="blue">infectious disease</font>     agents</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot accurately predict</font> the extent of <font color="blue">regulations</font> that     might result from any future <font color="blue">legislative</font> or <font color="blue">administrative</font> action</td>
    </tr>
    <tr>
      <td>Any of     these laws or <font color="blue">regulations</font> could cause us to incur <font color="blue"><font color="blue">additional</font> expense</font> or     restrict our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>OTHER RISKS RELATED TO OUR BUSINESS             Many of our <font color="blue">competitors</font> have <font color="blue">substantially</font> greater <font color="blue">capabilities</font> and     resources and may be able to develop and <font color="blue"><font color="blue">commercialize</font> products</font> before we     do</td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense competition from</font> a wide range of <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> companies, as well as academic and <font color="blue">research institutions</font> and     <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td><font color="blue">Principal </font><font color="blue"><font color="blue">competitive</font> factors</font> in our industry include:         •  the quality and breadth of an organization’s <font color="blue">technology</font>;         •  the skill of an organization’s employees and its ability to recruit and     retain <font color="blue">skilled employees</font>;         •  an organization’s <font color="blue">intellectual property</font> portfolio;         •  the range of <font color="blue">capabilities</font>, from target identification and <font color="blue">validation</font> to     drug <font color="blue">discovery</font> and <font color="blue">development</font> to <font color="blue">manufacturing</font> and marketing; and         •  the <font color="blue">availability</font> of substantial <font color="blue">capital resources</font> to fund <font color="blue">discovery</font>,     <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Many  large  <font color="blue">pharmaceutical</font>  and  bio<font color="blue">technology</font>  companies have     <font color="blue">significant</font>ly  larger  intellectual  <font color="blue">property estates than</font> we do, more     substantial <font color="blue">capital resources</font> than we have, and greater <font color="blue">capabilities</font> and     experience  than we do in preclinical and clinical <font color="blue">development</font>, sales,     marketing, <font color="blue">manufacturing</font> and <font color="blue">regulatory</font> affairs</td>
    </tr>
    <tr>
      <td>We are aware of products in research or <font color="blue">development</font> by our <font color="blue">competitors</font>     that address all of the diseases we are targeting</td>
    </tr>
    <tr>
      <td>Any of these products may     compete  with  our  product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> may</font> succeed in     developing their products before we do, obtaining <font color="blue">approvals from</font> the FDA or     other <font color="blue">regulatory</font> agencies for their products more rapidly than we do, or     developing products that are more <font color="blue">effective</font> than our                                         26       _________________________________________________________________           products</td>
    </tr>
    <tr>
      <td>These products or <font color="blue">technologies</font> might render our <font color="blue">technology</font> or     drugs under <font color="blue">development</font> obsolete or <font color="blue">non<font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>In addition, our albumin     fusion  protein  products are designed to be longer-acting versions of     <font color="blue"><font color="blue">existing product</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">existing product</font> in many cases has an established     market that may make the <font color="blue">introduction</font> of our product more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>If we lose or are unable to attract key <font color="blue">management</font> or other personnel,     we may experience delays in <font color="blue">product <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our <font color="blue">senior <font color="blue">executive officers</font> as well as key scientific</font>     and other personnel</td>
    </tr>
    <tr>
      <td>If any key employee decides to terminate his or her     <font color="blue">employment</font> with us, this <font color="blue">termination</font> could delay the <font color="blue">commercialization</font> of     our products or prevent us from becoming profitable</td>
    </tr>
    <tr>
      <td>We have not purchased     key-man life insurance on any of our <font color="blue">executive officers</font> or <font color="blue">key personnel</font>,     and <font color="blue">therefore may</font> not have <font color="blue">adequate funds</font> to find acceptable <font color="blue">replacements</font>     for  them</td>
    </tr>
    <tr>
      <td><font color="blue">Competition  </font>for  qualified  employees  is  intense  among     <font color="blue">pharmaceutical</font>  and bio<font color="blue">technology</font> companies, and the loss of qualified     employees, or an <font color="blue">inability</font> to attract, retain and motivate <font color="blue">additional</font> highly     <font color="blue">skilled employees</font> required for the expansion of our <font color="blue">activities</font>, could hinder     our ability to complete <font color="blue">human studies</font> <font color="blue">successfully</font> and develop marketable     products</td>
    </tr>
    <tr>
      <td>If the health care system or <font color="blue">reimbursement</font> policies change, the prices     of our <font color="blue">potential products</font> may be lower than expected and our potential sales     may decline</td>
    </tr>
    <tr>
      <td>The  levels  of revenues and <font color="blue">profitability</font> of bio<font color="blue">pharmaceutical</font>     companies like ours may be <font color="blue">affected by</font> the <font color="blue">continuing efforts</font> of <font color="blue">government</font>     and <font color="blue">third <font color="blue">party payers</font></font> to contain or reduce the costs of <font color="blue">health care through</font>     various  means</td>
    </tr>
    <tr>
      <td>For  example,  in certain foreign markets, pricing or     <font color="blue">profitability</font> of <font color="blue">therapeutic</font> and other <font color="blue">pharmaceutical</font> products is subject to     <font color="blue">government</font>al control</td>
    </tr>
    <tr>
      <td><font color="blue">In the US </font>there have been, and we expect that there     <font color="blue">will continue</font> to be, a number of federal and state proposals to implement     similar  <font color="blue">government</font>al  control</td>
    </tr>
    <tr>
      <td>While  we  <font color="blue">cannot predict whether</font> any     <font color="blue">legislative</font> or <font color="blue">regulatory</font> proposals will be adopted, the adoption of such     <font color="blue">proposals could</font> have a material adverse effect on our business, financial     condition and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">in the US </font>and elsewhere, sales     of <font color="blue">therapeutic</font> and other <font color="blue">pharmaceutical</font> products depend in part on the     <font color="blue">availability</font> of <font color="blue">reimbursement</font> to the consumer from <font color="blue">third <font color="blue">party payers</font></font>, such     as  <font color="blue">government</font>  and  private  insurance  plans</td>
    </tr>
    <tr>
      <td>Third <font color="blue">party payers</font> are     <font color="blue">increasingly</font>  <font color="blue">challenging</font>  the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and     services</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any of our <font color="blue">products will</font> be considered     cost <font color="blue">effective</font> or that <font color="blue">reimbursement</font> to the <font color="blue">consumer will</font> be available or     will be sufficient to allow us to sell our <font color="blue">products on</font> a <font color="blue">competitive</font> and     <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>We may be unable <font color="blue">successfully</font> to establish a <font color="blue">manufacturing</font> capability     and  may  be  unable  to  obtain  required  quantities of our products     <font color="blue">economically</font></td>
    </tr>
    <tr>
      <td>We do not <font color="blue">manufacture</font> any products for <font color="blue">commercial use</font> and do not have     any experience in <font color="blue">manufacturing</font> materials suitable for <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>We     are nearing the <font color="blue">completion</font> of <font color="blue">construction</font> and are beginning the <font color="blue">validation</font>     phase of a large-scale <font color="blue">manufacturing</font> <font color="blue">facility</font> to increase our <font color="blue">capacity</font> for     protein and <font color="blue">antibody drug production</font></td>
    </tr>
    <tr>
      <td>The FDA must inspect and license these     <font color="blue">facilities</font> to determine compliance with cGMP <font color="blue">requirements</font> for commercial     production</td>
    </tr>
    <tr>
      <td>We  may  not be able <font color="blue">successfully</font> to <font color="blue">establish sufficient</font>     <font color="blue">manufacturing</font> <font color="blue">capabilities</font> or <font color="blue">manufacture</font> our products <font color="blue">economically</font> or in     <font color="blue">compliance with cGMPs</font> and other <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>While  we are expanding our <font color="blue">manufacturing</font> <font color="blue">capabilities</font>, we have     contracted and may in the future contract with third party <font color="blue">manufacture</font>rs or     develop products with <font color="blue"><font color="blue">collaboration</font> partners</font> and use the <font color="blue">collaboration</font>     partners’ <font color="blue">manufacturing</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>If we use others to <font color="blue">manufacture</font> our     products, we <font color="blue">will <font color="blue">depend on</font></font> those parties to <font color="blue">comply with cGMPs</font>, and other     <font color="blue">regulatory</font> <font color="blue">requirements</font> and to deliver <font color="blue">materials on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">parties may</font> not perform <font color="blue">adequately</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">failures by</font> these <font color="blue">third parties</font> may     delay our <font color="blue">development</font> of products or the submission of these products for     <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>Because we currently have only a limited <font color="blue">marketing capability</font>, we may     be unable to sell any of our products <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>We do not have any <font color="blue">marketed products</font></td>
    </tr>
    <tr>
      <td>If we develop products that can     be  marketed, we intend to market the products either in<font color="blue">dependent</font>ly or     <font color="blue">together with</font> <font color="blue">collaborators</font> or <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>GSK and others                                         27       _________________________________________________________________           have co-marketing rights with respect to certain of our products</td>
    </tr>
    <tr>
      <td>If we     decide  to  market any products, either in<font color="blue">dependent</font>ly or <font color="blue">together with</font>     partners, we will incur <font color="blue">significant</font> <font color="blue">additional</font> <font color="blue"><font color="blue">expenditure</font>s</font> and commit     <font color="blue">significant</font> <font color="blue">additional</font> <font color="blue">management</font> resources to establish a <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>For     any products that we market <font color="blue">together with</font> partners, we will rely, in whole     or in part, on the marketing <font color="blue">capabilities</font> of those parties</td>
    </tr>
    <tr>
      <td>We may also     contract with <font color="blue">third parties</font> to <font color="blue">market certain</font> of our products</td>
    </tr>
    <tr>
      <td>Ultimately,     we and our <font color="blue">partners may</font> not be successful in marketing our products</td>
    </tr>
    <tr>
      <td>Because we <font color="blue">depend on</font> <font color="blue">third parties</font> to conduct some of our <font color="blue">laboratory</font>     testing and <font color="blue">human studies</font>, we <font color="blue">may encounter</font> delays in or lose some control     over our efforts to develop products</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> on third-party research organizations to design and     conduct some of our <font color="blue">laboratory</font> testing and <font color="blue">human studies</font></td>
    </tr>
    <tr>
      <td>If we are unable     to obtain any <font color="blue">necessary</font> testing services on acceptable terms, we may not     complete our <font color="blue">product <font color="blue">development</font></font> efforts in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>If we rely on     <font color="blue">third parties</font> for <font color="blue">laboratory</font> testing and <font color="blue">human studies</font>, we may lose some     <font color="blue">control over</font> these <font color="blue">activities</font> and become too <font color="blue">dependent</font> upon these parties</td>
    </tr>
    <tr>
      <td>These <font color="blue">third parties</font> may not complete testing <font color="blue">activities</font> on schedule or when     we request</td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font>, bylaws and <font color="blue">stockholder rights</font> plan     could discourage <font color="blue">acquisition</font> proposals, delay a change in control or prevent     <font color="blue">transaction</font>s that are in your <font color="blue"><font color="blue">best interest</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws, as well as     Section 203 of the Delaware General Corporation Law, may discourage, delay     or prevent a change in control of our company that you as a <font color="blue">stockholder may</font>     consider favorable and may be in your <font color="blue">best interest</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">also adopted</font> a     <font color="blue">stockholder rights</font> plan, or “<font color="blue">poison pill</font>,” that may discourage, delay or     prevent a change in control</td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws     <font color="blue">contain provisions</font> that:         •  authorize the issuance of up to 20cmam000cmam000 shares of “<font color="blue">blank check</font>”     <font color="blue">preferred stock</font> that could be issued by our board of <font color="blue">directors</font> to increase     the number of <font color="blue">outstanding shares</font> and discourage a <font color="blue">takeover attempt</font>;         •  classify the <font color="blue">directors</font> of our board with staggered, three-year terms,     which  may  lengthen the time required to <font color="blue">gain control</font> of our board of     <font color="blue">directors</font>;         •  limit who <font color="blue">may call special meetings</font> of <font color="blue">stockholders</font>; and         •  <font color="blue">establish advance</font> notice <font color="blue">requirements</font> for nomination of <font color="blue">candidates</font> for     election to the board of <font color="blue">directors</font> or for <font color="blue">proposing matters</font> that can be     acted upon by <font color="blue">stockholders</font> at stockholder meetings</td>
    </tr>
    <tr>
      <td>Because our stock price has been and <font color="blue">will likely continue</font> to be     volatile, the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> may</font> be lower or more volatile     than you expected</td>
    </tr>
    <tr>
      <td>Our stock price, like the <font color="blue">stock prices</font> of many other bio<font color="blue">technology</font>     companies,  has  been  highly  volatile</td>
    </tr>
    <tr>
      <td><font color="blue">From January </font>1, 2005 through     <font color="blue">December </font>31, 2005, the closing price of our <font color="blue">common stock</font> has <font color="blue">been as low as</font>     dlra7dtta75 per share and as high as dlra15dtta08 per share</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our     <font color="blue">common stock</font> could fluctuate widely because of:         •  <font color="blue">future <font color="blue">announcements</font> about</font> our company or our <font color="blue">competitors</font>, including     the results of testing, technological innovations or <font color="blue">new commercial</font>     products;         •  negative <font color="blue">regulatory</font> actions with respect to our <font color="blue">potential products</font> or     <font color="blue"><font color="blue">regulatory</font> approvals</font> with respect to our <font color="blue">competitors</font>’ products;         •  changes in <font color="blue">government</font> <font color="blue">regulations</font>;         •  <font color="blue">development</font>s in our <font color="blue">relationships with</font> our <font color="blue"><font color="blue">collaboration</font> partners</font>;         •  <font color="blue">development</font>s affecting our <font color="blue"><font color="blue">collaboration</font> partners</font>;         •  <font color="blue">announcements</font> relating to <font color="blue">health care reform</font> and <font color="blue">reimbursement</font> levels     for new drugs, particularly oncology drugs;                                         28       _________________________________________________________________             •  our failure to acquire or maintain <font color="blue">proprietary</font> rights to the gene     sequences we discover or the products we develop;         •  <font color="blue">litigation</font>; and         •  public concern as to the safety of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market</font> has experienced <font color="blue">extreme price</font> and <font color="blue">volume <font color="blue">fluctuations</font></font>     that have <font color="blue">particularly affected</font> the <font color="blue">market price</font> for many emerging and     bio<font color="blue">technology</font> companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations</font> have often been unrelated to the     operating performance of these companies</td>
    </tr>
    <tr>
      <td>These broad market <font color="blue">fluctuations</font>     may cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to be lower or more volatile     than you expected</td>
    </tr>
  </tbody>
</table>